NSI-189

Overview

NSI-189 (NSI-189 phosphate) is a small-molecule compound developed by Neuralstem, Inc., discovered through a proprietary in vitro screen designed to identify chemicals that stimulate the proliferation of human hippocampal neural stem cells. Unlike conventional antidepressants that modulate monoamine neurotransmitter levels (SSRIs, SNRIs, TCAs, MAOIs), NSI-189 represents a fundamentally novel mechanistic approach to depression treatment based on the neurogenic hypothesis — the theory that major depressive disorder (MDD) is associated with impaired hippocampal neurogenesis and reduced hippocampal volume, and that therapeutic interventions should directly restore these deficits. MRI volumetric studies consistently demonstrate hippocampal atrophy of 5–15% in depressed patients, and hippocampal volume correlates with treatment response and remission.

In Phase I clinical trials, NSI-189 (40 mg daily for 28 days) demonstrated significant improvements in depression scores (Montgomery-Asberg Depression Rating Scale) and cognitive measures (Cognitive and Physical Functioning Questionnaire) in patients with MDD. Notably, MRI analysis revealed a trend toward increased hippocampal volume in the treated group — a finding that, if confirmed, would represent the first demonstration of a psychiatric drug directly reversing hippocampal atrophy. The Phase II randomized, double-blind, placebo-controlled trial tested doses of 40 mg and 80 mg daily for 12 weeks. While the primary endpoint (change in MADRS) did not achieve statistical significance versus placebo (partly due to a high placebo response rate), secondary analyses showed significant improvements in cognitive function and several depression subscales, particularly at the 40 mg dose. Patient-reported outcomes and clinician-assessed measures diverged, with patients reporting more robust improvement than clinician ratings captured.

The precise molecular target of NSI-189 remains partially elucidated. Research indicates it may modulate the phosphatidic acid signaling pathway and interact with molecules involved in neuroplasticity, including BDNF signaling and Akt/mTOR pathways. The compound increases hippocampal volume and long-term potentiation (LTP) in animal models while improving performance on hippocampus-dependent learning and memory tasks. In the nootropic and research communities, NSI-189 has generated significant interest as a potential cognitive enhancer independent of its antidepressant application, given its unique ability to promote adult hippocampal neurogenesis — a process that declines with age and is implicated in age-related cognitive decline. NSI-189 is typically discussed alongside other neuroplasticity-promoting compounds such as Semax, lion's mane, and dihexa. Neuralstem continues to explore the compound's development pathway, and it remains investigational without regulatory approval.

Mechanism of Action

NSI-189 is a benzylpiperazine-aminopyridine compound that stimulates neurogenesis in the hippocampus through a mechanism that is not fully elucidated but involves modulation of several key pathways. Its primary molecular target appears to be related to enhancement of hippocampal volume and function, with evidence suggesting it increases phosphorylation of CREB (cAMP response element-binding protein) and its downstream target BDNF (brain-derived neurotrophic factor) in hippocampal neurons. NSI-189 promotes proliferation and differentiation of neural progenitor cells in the dentate gyrus subgranular zone, one of only two brain regions where adult neurogenesis occurs.

NSI-189 has been shown to activate the Akt/PKB signaling pathway and enhance Wnt/beta-catenin signaling, both of which are critical regulators of neural stem cell self-renewal and differentiation. It upregulates synaptic markers including synaptophysin, PSD-95, and AMPA receptor subunits (GluA1), indicating enhancement of both pre- and post-synaptic function. The compound also modulates the HPA (hypothalamic-pituitary-adrenal) axis by reducing elevated cortisol levels, which is significant because chronic hypercortisolemia suppresses hippocampal neurogenesis and contributes to hippocampal atrophy observed in major depressive disorder. NSI-189 additionally enhances long-term potentiation (LTP) in hippocampal circuits, improving the synaptic plasticity underlying learning and memory.

Therapeutically, NSI-189 was developed specifically for major depressive disorder (MDD) based on the neurogenesis hypothesis of depression, which links hippocampal atrophy and reduced neurogenesis to depressive pathology. Phase 2 clinical trials demonstrated improvements in cognitive function and depressive symptoms, with MRI evidence suggesting increased hippocampal volume. Its mechanism is distinct from monoamine-based antidepressants, offering potential benefits for treatment-resistant depression. NSI-189 also shows promise for cognitive impairment associated with aging, PTSD, and traumatic brain injury through its pro-neurogenic and synaptic enhancement properties.

Reconstitution Calculator

Research

Safety Profile

NSI-189 is an investigational compound with limited clinical safety data. Reported side effects in trials include headache, insomnia, and mild cognitive disturbances. It should not be used by individuals with a history of seizures or severe psychiatric disorders, and it is contraindicated during pregnancy and breastfeeding due to unknown teratogenic risks.

Pharmacokinetic Profile